Serious infections in hospitalized patients with psoriasis in the United States - 20/07/16
Abstract |
Background |
Patients with psoriasis have multiple risk factors for serious infections, including immune dysregulation, systemic immunosuppressive medications, and comorbid health conditions.
Objective |
We sought to determine rates and predictors of serious infections in hospitalized psoriasis patients and quantify costs of care, length of stay, and mortality.
Methods |
We conducted a cross-sectional study of the Nationwide Inpatient Sample from 2002 to 2012, containing a representative 20% sample of all hospitalizations in the United States.
Results |
In multivariate logistic regression models, psoriasis was associated with multiple serious infections, including methicillin-resistant Staphylococcus aureus (odds ratio [OR] 1.76, 95% confidence intervals [CI] 1.52-2.03), cellulitis (OR 3.21, 95% CI 3.12-3.30), herpes simplex virus infection (OR 2.21, 95% CI 1.70-2.89), infectious arthritis (OR 1.82, 95% CI 1.58-2.09), osteomyelitis (OR 1.31, 95% CI 1.18-1.46), meningitis (OR 1.31, 95% CI 1.16-1.47), encephalitis (OR 1.22, 95% CI 1.02-1.47), and tuberculosis (OR 1.34, 95% CI 1.20-1.49). Among patients with psoriasis, rates of serious infections increased over all time intervals analyzed (P = .01) and were significantly higher compared with those without psoriasis across all time intervals (P < .0001). The mean length of stay (6.6 ± 0.1 days) and cost of care ($13,291 ± $166) for psoriasis patients with serious infections was higher than that of psoriasis patients without serious infections (4.6 ± 0.03 days; $11,003 ± $96; P < .0001).
Limitations |
The study was limited to inpatients. Medication data were not available.
Conclusion |
Serious infections are increasing in incidence in US inpatients with psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : biologics, cost of care, hospitalization, length of stay, methotrexate, psoriasis, serious infection
Abbreviations used : CI, HCUP, ICD-9-CM, LOS, MRSA, MSSA, NIS, OR
Plan
| This publication was made possible with support from the Agency for Healthcare Research and Quality, grant number K12HS023011, the Dermatology Foundation. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. |
|
| Conflicts of interest: None declared. |
Vol 75 - N° 2
P. 287-296 - août 2016 Retour au numéro
Article précédent
- Change of Address
- OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
- Jon M. Hanifin, Charles N. Ellis, Ilona J. Frieden, Regina Fölster-Holst, Linda F. Stein Gold, Angelo Secci, Angela J. Smith, Cathy Zhao, Elena Kornyeyeva, Lawrence F. Eichenfield
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?